Improving care for patients with chronic heart failure in the community: The importance of a disease management program

Chest

Volumn 122, Issue 3, 2002, Pages 906-912

  Akosah, Kwame O ^a   Schaper, Ana M ^a   Havlik, Paul ^a   Barnhart, Sharon ^a   Devine, Stephen ^a  

^a GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

Author keywords

Congestive heart failure; Disease management; Outcomes

Indexed keywords

LISINOPRIL;

ADULT; AGED; ARTICLE; COMMUNITY; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH CENTER; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HOSPITAL DISCHARGE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATIENT CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

EID: 0036382975     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.122.3.906     Document Type: Article

References (19)

1. American Heart Association 2002 Heart and Stroke Statistical Update. Available at: http://www.americanheart.org/statistics/ coronary.html. Accessed August 8, 2002
2. McGovern PG, Jacobs DR, Shahar E, et al. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota Heart Survey. Circulation 2001; 104:19-24
3. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the National Conference on Cardiovascular Disease Prevention. Circulation 2000; 102:3137-3147
4. Krumholz HM, Parent EM, Tu N, et al. Remission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 1997; 157:99-104
5. Packer M, Poole-Wilson A, Armstrong PW. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100:2312-2318
6. The International Steering Committee on behalf of the MERIT-HF Study Group. Rationale, design, and organization of the Metoprolol CFR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). Am J Cardiol 1997; 80:54J-58J
7. Pitt B, Zannad F, Remme WJ, et al. The effect of spirono-lactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717
8. Baker DW, Hayes RP, Massie BM, et al. Variations in family physicians' and cardiologists' care for patients with heart failure. Am Heart J 1999; 138:826-834
9. Echemann M, Zannad F, Briancon S, et al. Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction. Am Heart J 2000; 139:624-631
10. Philben EF, Andreou C, Rocco T, et al. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 1996; 77:832-838
11. Roe CM, Motheral BR, Teitelbaum F, et al. Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure. Am Heart J 1999; 138:818-825
12. Akosah KO, Moncher K, Schaper A, et al. Chronic heart failure in the community: missed diagnosis and missed opportunities. J Card Fail 2001; 7:232-238
13. Davies MK, Hobbs FD, Ravis RC, et al. Prevalence of left ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population-based study. Lancet 2001; 358:439-444
14. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651-1658
15. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2445
16. Cline CMJ, Israelsson BYA, Willenheimer RB, et al. Cost effective management programme for heart failure reduces hospitalization. Heart 1998; 80:442-446
17. Fonarow GC, Stevenson LW, Walden JA. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol 1997; 30:725-732
18. Ramahi T, Longo MD, Rohlfs K, et al. Effect of heart failure program on cardiovascular drug utilization and dosage in patients with chronic heart failure. Clin Cardiol 2000; 23: 909-914
19. Whellan DJ, Gaulden L, Gattis WA, et al. The benefit of implementing a heart failure disease management program. Arch Intern Med 2001; 161:2223-2228